ProPhase Labs, Inc. completed a conversion of $3.3 million of its outstanding convertible debt into common stock at a floor price of $0.76 per share, a level well above the company’s then‑trading price. The transaction eliminated the majority of the company’s $3.8 million principal debt, leaving an unconverted balance of less than $500,000 and improving the debt‑to‑equity ratio.
Continue reading for full analysis...